Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

• Main Authors: Joseph M. Unger (Author), Katherine Griffin (Author), Gary W. Donaldson (Author), Karen M. Baranowski (Author), Margorie J. Good (Author), Eunicia Reburiano (Author), Maha Hussain (Author), Paul J. Monk (Author), Peter J. Van Veldhuizen (Author), Michael A. Carducci (Author), Celestia S. Higano (Author), Primo N. Lara (Author), Catherine M. Tangen (Author), David I. Quinn (Author), James L. Wade (Author), III (Author), Nicholas J. Vogelzang (Author), Ian M. Thompson (Author), Jr (Author), Carol M. Moinpour (Author)
• Format: Book
• Published: SpringerOpen, 2018-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background SWOG S0421 was a large randomized trial comparing docetaxel/prednisone plus placebo (DPP) to docetaxel/prednisone plus atrasentan over 12 cycles for patients with metastatic castration-resistant prostate cancer (mCRPC). The current report presents the PRO results for this trial,...